Stratified medicine for pancreatic cancer

Chang, D. K. , Jamieson, N. B. , Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi: 10.1016/B978-0-12-386882-4.00034-7)

Full text not currently available from Enlighten.

Publisher's URL:


Pancreatic cancer (PC) is the fourth leading cause of cancer-related death in western societies, including the United Kingdom, and has a 5-year survival of <5%. Recent large-scale genomic sequencing efforts suggest that, apart from a few that cannot be effectively targeted, mutations occur at a rate of less than 2%, making PC one of the most genomically diverse cancers. This heterogeneity may explain the multiple failed chemotherapeutic trials in the past; at the least, it creates an opportunity to explore a stratified approach based on molecular phenotype. In this chapter, we examine existing evidence and explore a potential stratified approach for PC treatment.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Jamieson, Dr Nigel and Biankin, Professor Andrew and Grimmond, Professor Sean and Chang, Professor David
Authors: Chang, D. K., Jamieson, N. B., Grimmond, S. M., and Biankin, A. V.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Published Online:02 May 2014

University Staff: Request a correction | Enlighten Editors: Update this record